1. **NAME OF THE MEDICINAL PRODUCT**

INVANZ 1 g powder for concentrate for solution for infusion

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each vial contains 1.0 g ertapenem.

*Excipient(s) with known effect*

Each 1.0 g dose contains approximately 6.0 mEq of sodium (approximately 137 mg).

For the full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

Powder for concentrate for solution for infusion.

White to off-white powder.

4. **CLINICAL PARTICULARS**

4.1 **Therapeutic indications**

_Treatment_

INVANZ is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4.4 and 5.1):

- Intra-abdominal infections
- Community acquired pneumonia
- Acute gynaecological infections
- Diabetic foot infections of the skin and soft tissue (see section 4.4)

_Prevention_

INVANZ is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4.4).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

4.2 **Posology and method of administration**

_Posology_

_Treatment_

*Adults and adolescents (13 to 17 years of age)*: The dose of INVANZ is 1 gram (g) given once a day by the intravenous route (see section 6.6).

*Infants and children (3 months to 12 years of age)*: The dose of INVANZ is 15 mg/kg given twice daily (not to exceed 1 g/day) by the intravenous route (see section 6.6).
Prevention

Adults: To prevent surgical site infections following elective colorectal surgery, the recommended dosage is 1 g administered as a single intravenous dose to be completed within 1 hour prior to the surgical incision.

Paediatric population

The safety and efficacy of INVANZ in children below 3 months of age have not yet been established. No data are available.

Renal impairment

INVANZ may be used for the treatment of infections in adult patients with mild to moderate renal impairment. In patients whose creatinine clearance is > 30 mL/min/1.73 m², no dosage adjustment is necessary. There are inadequate data on the safety and efficacy of ertapenem in patients with severe renal impairment to support a dose recommendation. Therefore, ertapenem should not be used in these patients (see section 5.2.). There are no data in children and adolescents with renal impairment.

Haemodialysis

There are inadequate data on the safety and efficacy of ertapenem in patients on haemodialysis to support a dose recommendation. Therefore, ertapenem should not be used in these patients.

Hepatic impairment

No dosage adjustment is recommended in patients with impaired hepatic function (see section 5.2).

Elderly

The recommended dose of INVANZ should be administered, except in cases of severe renal impairment (see Renal impairment).

Method of administration

Intravenous administration: INVANZ should be infused over a period of 30 minutes.

The usual duration of therapy with INVANZ is 3 to 14 days but may vary depending on the type and severity of infection and causative pathogen(s). When clinically indicated, a switch to an appropriate oral antibacterial agent may be implemented if clinical improvement has been observed.

For instructions on preparation of the medicinal product before administration, see section 6.6.

4.3 Contraindications

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
- Hypersensitivity to any other carbapenem antibacterial agent
- Severe hypersensitivity (e.g., anaphylactic reaction, severe skin reaction) to any other type of beta-lactam antibacterial agent (e.g., penicillins or cephalosporins).

4.4 Special warnings and precautions for use

Hypersensitivity

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta-lactams. These reactions are more likely to occur in individuals with a history of sensitivity to multiple allergens. Before initiating therapy with ertapenem, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, other beta-lactams and other allergens (see section 4.3). If an allergic reaction to ertapenem occurs (see section 4.8), discontinue the therapy immediately. Serious anaphylactic reactions require immediate emergency treatment.
Superinfection
Prolonged use of ertapenem may result in overgrowth of non-susceptible organisms. Repeated evaluation of the patient's condition is essential. If superinfection occurs during therapy, appropriate measures should be taken.

Antibiotic-associated colitis
Antibiotic-associated colitis and pseudomembranous colitis have been reported with ertapenem and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea subsequent to the administration of antibacterial agents. Discontinuation of therapy with INVANZ and the administration of specific treatment for Clostridioides difficile should be considered. Medicinal products that inhibit peristalsis should not be given.

Seizures
Seizures have been reported during clinical investigation in adult patients treated with ertapenem (1 g once a day) during therapy or in the 14-day follow-up period. Seizures occurred most commonly in elderly patients and those with pre-existing central nervous system (CNS) disorders (e.g. brain lesions or history of seizures) and/or compromised renal function. Similar observations have been made in the post-marketing environment.

Encephalopathy
Encephalopathy has been reported with the use of ertapenem (see section 4.8). If ertapenem-induced encephalopathy is suspected (e.g. myoclonus, seizures, altered mental status, depressed level of consciousness), discontinuation of ertapenem should be considered. Patients with renal impairment are at higher risk of ertapenem-induced encephalopathy and the resolution may be prolonged.

Concomitant use with valproic acid
The concomitant use of ertapenem and valproic acid/sodium valproate is not recommended (see section 4.5).

Sub-optimal exposure
Based on the data available it cannot be excluded that in the few cases of surgical interventions exceeding 4 hours, patients could be exposed to sub-optimal ertapenem concentrations and consequently to a risk of potential treatment failure. Therefore, caution should be exercised in such unusual cases.

Considerations for use in particular populations
Experience in the use of ertapenem in the treatment of severe infections is limited. In clinical studies for the treatment of community-acquired pneumonia, in adults, 25% of evaluable patients treated with ertapenem had severe disease (defined as pneumonia severity index > III). In a clinical study for the treatment of acute gynaecologic infections, in adults, 26% of evaluable patients treated with ertapenem had severe disease (defined as temperature ≥ 39°C and/or bacteraemia); ten patients had bacteraemia. Of evaluable patients treated with ertapenem in a clinical study for the treatment of intra-abdominal infections, in adults, 30% had generalised peritonitis and 39% had infections involving sites other than the appendix including the stomach, duodenum, small bowel, colon, and gallbladder; there were limited numbers of evaluable patients who were enrolled with APACHE II scores ≥ 15 and efficacy in these patients has not been established.

The efficacy of INVANZ in the treatment of community acquired pneumonia due to penicillin-resistant Streptococcus pneumoniae has not been established.

Efficacy of ertapenem in the treatment of diabetic foot infections with concurrent osteomyelitis has not been established.

There is relatively little experience with ertapenem in children less than two years of age. In this age group, particular care should be taken to establish the susceptibility of the infecting organism(s) to ertapenem. No data are available in children under 3 months of age.
Sodium
This medicinal product contains approximately 137 mg sodium per 1.0 g dose, equivalent to 6.85 % of the WHO recommended maximum daily intake of 2 g sodium for an adult.

4.5 Interaction with other medicinal products and other forms of interaction

Interactions caused by inhibition of P-glycoprotein-mediated clearance or CYP-mediated clearance of medicinal products are unlikely (see section 5.2).

Decreases in valproic acid levels that may fall below the therapeutic range have been reported when valproic acid was co-administered with carbapenem agents. The lowered valproic acid levels can lead to inadequate seizure control; therefore, concomitant use of ertapenem and valproic acid/sodium valproate is not recommended and alternative antibacterial or anti-convulsant therapies should be considered.

4.6 Fertility, pregnancy and lactation

Pregnancy
Adequate and well-controlled studies have not been performed in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryo-foetal development, parturition or post-natal development. However, ertapenem should not be used during pregnancy unless the potential benefit outweighs the possible risk to the foetus.

Breast-feeding
Ertapenem is excreted in human milk. Because of the potential for adverse reactions on the infant, mothers should not breast-feed their infants while receiving ertapenem.

Fertility
There are no adequate and well-controlled studies regarding the effect of ertapenem use on fertility in men and women. Preclinical studies do not indicate direct or indirect harmful effects with respect to fertility (see section 5.3).

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed.

INVANZ may influence patients' ability to drive and use machines. Patients should be informed that dizziness and somnolence have been reported with INVANZ (see section 4.8).

4.8 Undesirable effects

Summary of the safety profile

Adults
The total number of patients treated with ertapenem in clinical studies was over 2,200 of which over 2,150 received a 1 g dose of ertapenem. Adverse reactions (i.e., considered by the investigator to be possibly, probably, or definitely related to the medicinal product) were reported in approximately 20 % of patients treated with ertapenem. Treatment was discontinued due to adverse reactions in 1.3 % of patients. An additional 476 patients received ertapenem as a single 1 g dose prior to surgery in a clinical study for the prophylaxis of surgical site infections following colorectal surgery.

For patients who received only INVANZ, the most common adverse reactions reported during therapy plus follow-up for 14 days after treatment was stopped were: diarrhoea (4.8 %), infused vein complication (4.5 %) and nausea (2.8 %).

For patients who received only INVANZ, the most frequently reported laboratory abnormalities and their respective incidence rates during therapy plus follow-up for 14 days after treatment was stopped
were: elevations in ALT (4.6 %), AST (4.6 %), alkaline phosphatase (3.8 %) and platelet count (3.0 %).

**Paediatric population (3 months to 17 years of age):**
The total number of patients treated with ertapenem in clinical studies was 384. The overall safety profile is comparable to that in adult patients. Adverse reactions (i.e., considered by the investigator to be possibly, probably, or definitely related to the medicinal product) were reported in approximately 20.8 % of patients treated with ertapenem. Treatment was discontinued due to adverse reactions in 0.5 % of patients.

For patients who received only INVANZ, the most common adverse reactions reported during therapy plus follow-up for 14 days after treatment was stopped were: diarrhoea (5.2 %) and infusion site pain (6.1 %).

For patients who received only INVANZ, the most frequently reported laboratory abnormalities and their respective incidence rates during therapy plus follow-up for 14 days after treatment was stopped were: decreases in neutrophil count (3.0 %), and elevations in ALT (2.9 %) and AST (2.8 %).

**Tabulated list of adverse reactions**
For patients who received only INVANZ, the following adverse reactions were reported during therapy plus follow-up for 14 days after treatment was stopped:

<p>| Common (≥ 1/100 to &lt; 1/10); Uncommon (≥ 1/1,000 to &lt; 1/100); Rare (≥ 1/10,000 to &lt; 1/1,000); Very rare (&lt; 1/10,000); Not known (cannot be estimated from the available data) |
|---|---|
| <strong>Adults 18 years of age and older</strong> | <strong>Children and adolescents (3 months to 17 years of age)</strong> |
| <strong>Infections and infestations</strong> | Uncommon: Oral candidiasis, candidiasis, fungal infection, pseudomembranous enterocolitis, vaginitis Rare: Pneumonia, dermatomycosis, postoperative wound infection, urinary tract infection |
| Blood and lymphatic system disorders | Rare: Neutropenia, thrombocytopenia |
| Immune system disorders | Rare: Allergy Not known: Anaphylaxis including anaphylactoid reactions |
| Metabolism and nutrition disorders | Uncommon: Anorexia Rare: Hypoglycaemia |
| Psychiatric disorders | Uncommon: Insomnia, confusion Rare: Agitation, anxiety, depression Not known: Altered mental status (including aggression) |
| | Not known: Altered mental status (including aggression) |</p>
<table>
<thead>
<tr>
<th>Category</th>
<th>Adults 18 years of age and older</th>
<th>Children and adolescents (3 months to 17 years of age)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nervous system disorders</td>
<td><em>Common</em>: Headache&lt;br&gt; <em>Uncommon</em>: Dizziness, somnolence, taste perversion, seizure (see section 4.4)&lt;br&gt; <em>Rare</em>: Tremor, syncope&lt;br&gt; <em>Not known</em>: Hallucinations, depressed level of consciousness, dyskinesia, myoclonus, gait disturbance, encephalopathy (see section 4.4)</td>
<td><em>Uncommon</em>: Headache&lt;br&gt; <em>Not known</em>: Hallucinations</td>
</tr>
<tr>
<td>Eye disorders</td>
<td><em>Rare</em>: Scleral disorder&lt;br&gt;</td>
<td></td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td><em>Uncommon</em>: Sinus bradycardia&lt;br&gt; <em>Rare</em>: Arrhythmia, tachycardia</td>
<td></td>
</tr>
<tr>
<td>Vascular disorders</td>
<td><em>Common</em>: Infused vein complication, phlebitis/thrombophlebitis&lt;br&gt; <em>Uncommon</em>: Hypotension&lt;br&gt; <em>Rare</em>: Haemorrhage, increased blood pressure</td>
<td><em>Uncommon</em>: Hot flush, hypertension</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td><em>Uncommon</em>: Dyspnoea, pharyngeal discomfort&lt;br&gt; <em>Rare</em>: Nasal congestion, cough, epistaxis, rales/rhonchi, wheezing</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td><em>Common</em>: Diarrhoea, nausea, vomiting&lt;br&gt; <em>Uncommon</em>: Constipation, acid regurgitation, dry mouth, dyspepsia, abdominal pain&lt;br&gt; <em>Rare</em>: Dysphagia, faecal incontinence, pelvic peritonitis&lt;br&gt; <em>Not known</em>: teeth staining</td>
<td><em>Common</em>: Diarrhoea&lt;br&gt; <em>Uncommon</em>: Faeeces discoloured, melaena</td>
</tr>
<tr>
<td>Hepatobiliary disorders</td>
<td><em>Rare</em>: Cholecystitis, jaundice, liver disorder</td>
<td><em>Common</em>: Diaper dermatitis&lt;br&gt; <em>Uncommon</em>: Erythema, rash, petechiae</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td><em>Common</em>: Rash, pruritus&lt;br&gt; <em>Uncommon</em>: Erythema, urticaria&lt;br&gt; <em>Rare</em>: Dermatitis, desquamation, hypersensitivity vasculitis&lt;br&gt; <em>Not known</em>: Acute Generalised Exanthematous Pustulosis (AGEP), Drug Rash with Eosinophilia and Systemic Symptoms (DRESS syndrome)</td>
<td></td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td><em>Rare</em>: Muscle cramp, shoulder pain&lt;br&gt; <em>Not known</em>: Muscular weakness</td>
<td></td>
</tr>
<tr>
<td>Renal and urinary disorders</td>
<td><em>Rare</em>: Renal insufficiency, acute renal insufficiency</td>
<td></td>
</tr>
<tr>
<td>Pregnancy, puerperium and perinatal conditions</td>
<td><em>Rare</em>: Abortion</td>
<td></td>
</tr>
<tr>
<td>Reproductive system and breast disorders</td>
<td><em>Rare</em>: Genital bleeding</td>
<td></td>
</tr>
<tr>
<td><strong>General disorders and administration site conditions</strong></td>
<td>Adults 18 years of age and older</td>
<td>Children and adolescents (3 months to 17 years of age)</td>
</tr>
<tr>
<td>----------------------------------------------------------</td>
<td>-------------------------------</td>
<td>-------------------------------------------------</td>
</tr>
<tr>
<td><strong>Uncommon</strong>: Extravasation, asthenia/fatigue, fever, oedema/swelling, chest pain</td>
<td><strong>Common</strong>: Infusion site pain</td>
<td><strong>Uncommon</strong>: Infusion site burning, infusion site pruritus, infusion site erythema, injection site erythema, infusion site warmth</td>
</tr>
<tr>
<td><strong>Rare</strong>: Injection-site induration, malaise</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Investigations</strong></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th><strong>Chemistry</strong></th>
<th>Adults 18 years of age and older</th>
<th>Children and adolescents (3 months to 17 years of age)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Common</strong>: Elevations in ALT, AST, alkaline phosphatase</td>
<td></td>
<td><strong>Common</strong>: Elevations in ALT and AST</td>
</tr>
<tr>
<td><strong>Uncommon</strong>: Increases in total serum bilirubin, direct serum bilirubin, indirect serum bilirubin, serum creatinine, serum urea, serum glucose</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Rare</strong>: Decreases in serum bicarbonate, serum creatinine, and serum potassium; increases in serum LDH, serum phosphorus, serum potassium</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Haematology</strong></th>
<th>Adults 18 years of age and older</th>
<th>Children and adolescents (3 months to 17 years of age)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Common</strong>: Elevation in platelet count</td>
<td></td>
<td><strong>Common</strong>: Decreases in neutrophil count</td>
</tr>
<tr>
<td><strong>Uncommon</strong>: Decreases in white blood cells, platelet count, segmented neutrophils, haemoglobin and haematocrit; increases in eosinophils, activated partial thromboplastin time, prothrombin time, segmented neutrophils, and white blood cells</td>
<td></td>
<td><strong>Uncommon</strong>: Increases in platelet count, activated partial thromboplastin time, prothrombin time, decreases in haemoglobin</td>
</tr>
<tr>
<td><strong>Rare</strong>: Decrease in lymphocytes; increases in band neutrophils, lymphocytes, metamyelocytes, monocytes, myelocytes; atypical lymphocytes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Urinalysis</strong></th>
<th>Adults 18 years of age and older</th>
<th>Children and adolescents (3 months to 17 years of age)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Uncommon</strong>: Increases in urine bacteria, urine white blood cells, urine epithelial cells, and urine red blood cells; urine yeast present</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Rare</strong>: Increase in urobilinogen</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Miscellaneous</strong></th>
<th>Adults 18 years of age and older</th>
<th>Children and adolescents (3 months to 17 years of age)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Uncommon</strong>: Positive Clostridioides difficile toxin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

**4.9 Overdose**

No specific information is available on the treatment of overdose with ertapenem. Overdosing of ertapenem is unlikely. Intravenous administration of ertapenem at a 3 g daily dose for 8 days to healthy adult volunteers did not result in significant toxicity. In clinical studies in adults inadvertent administration of up to 3 g in a day did not result in clinically important adverse reactions. In
paediatric clinical studies, a single intravenous (IV) dose of 40 mg/kg up to a maximum of 2 g did not result in toxicity.

However, in the event of an overdose, treatment with INVANZ should be discontinued and general supportive treatment given until renal elimination takes place.

Ertapenem can be removed to some extent by haemodialysis (see section 5.2); however, no information is available on the use of haemodialysis to treat overdose.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

General properties
Pharmacotherapeutic group: Antibacterials for systemic use, carbapenems, ATC code: J01DH03

Mechanism of action
Ertapenem inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). In *Escherichia coli*, affinity is strongest to PBPs 2 and 3.

Pharmacokinetic/Pharmacodynamic (PK/PD) relationship
Similar to other beta-lactam antimicrobial agents, the time that the plasma concentration of ertapenem exceeds the MIC of the infecting organism has been shown to best correlate with efficacy in pre-clinical PK/PD studies.

Mechanism of resistance
For species considered susceptible to ertapenem, resistance was uncommon in surveillance studies in Europe. In resistant isolates, resistance to other antibacterial agents of the carbapenem class was seen in some but not all isolates. Ertapenem is effectively stable to hydrolysis by most classes of beta-lactamases, including penicillinas, cephalosporinases and extended spectrum beta-lactamases, but not metallo-beta-lactamases.

Methicillin-resistant staphylococci and enterococci are resistant to ertapenem, owing to PBP target insensitivity; *P. aeruginosa* and other non-fermentative bacteria are generally resistant, probably owing to limited penetration and to active efflux.

Resistance is uncommon in Enterobacteriaceae and ertapenem is generally active against those with extended-spectrum beta-lactamases (ESBLs). Resistance can however be observed when ESBLs or other potent beta-lactamases (e.g. AmpC types) are present in conjunction with reduced permeability, arising by the loss of one or more outer membrane porins, or with up-regulated efflux. Resistance can also arise via the acquisition of beta-lactamases with significant carbapenem-hydrolysing activity (e.g. IMP and VIM metallo-beta-lactamases or KPC types), though these are rare.

The mechanism of action of ertapenem differs from that of other classes of antibiotics, such as quinolones, aminoglycosides, macrolides and tetracyclines. There is no target-based cross-resistance between ertapenem and these substances. However, micro-organisms may exhibit resistance to more than one class of antibacterial agents when the mechanism is, or includes, impermeability to some compounds and/or an efflux pump.

**Breakpoints**

The EUCAST MIC breakpoints are as follows:

- **Enterobacterales: S \leq 0.5 \text{ mg/L and } R > 0.5 \text{ mg/L}**
- **Streptococcus pneumoniae: S \leq 0.5 \text{ mg/L and } R > 0.5 \text{ mg/L}**
- *Haemophilus influenzae*: $S \leq 0.5 \text{ mg/L and } R > 0.5 \text{ mg/L}$
- *M. catarrhalis*: $S \leq 0.5 \text{ mg/L and } R > 0.5 \text{ mg/L}$
- *Gram negative anaerobes*: $S \leq 0.5 \text{ mg/L and } R > 0.5 \text{ mg/L}$
- *Gram positive anaerobes*: $S \leq 0.5 \text{ mg/L and } R > 0.5 \text{ mg/L}$
- *Viridans group streptococci*: $S \leq 0.5 \text{ mg/L and } R > 0.5 \text{ mg/L}$
- *Non species related breakpoints*: $S \leq 0.5 \text{ mg/L and } R > 0.5 \text{ mg/L}$

(NB: Susceptibility of staphylococci to ertapenem is inferred from methicillin susceptibility and susceptibility of group A, B, C,& G streptococci is inferred from benzylpenicillin susceptibility)

The prescribers are informed that local MIC breakpoints, if available, should be consulted.

**Microbiological susceptibility**

The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. Localised clusters of infections due to carbapenem-resistant organisms have been reported in the European Union. The information below gives only approximate guidance on the probability as to whether the micro-organism will be susceptible to ertapenem or not.

<table>
<thead>
<tr>
<th>Commonly susceptible species:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gram-positive aerobes:</strong></td>
</tr>
<tr>
<td>Methicillin-susceptible-staphylococci (including <em>Staphylococcus aureus)</em></td>
</tr>
<tr>
<td><em>Streptococcus agalactiae</em></td>
</tr>
<tr>
<td><em>Streptococcus pneumoniae</em>†</td>
</tr>
<tr>
<td><em>Streptococcus pyogenes</em></td>
</tr>
<tr>
<td><strong>Gram-negative aerobes:</strong></td>
</tr>
<tr>
<td><em>Citrobacter freundii</em></td>
</tr>
<tr>
<td><em>Enterobacter aerogenes</em></td>
</tr>
<tr>
<td><em>Enterobacter cloacae</em></td>
</tr>
<tr>
<td><em>Escherichia coli</em></td>
</tr>
<tr>
<td><em>Haemophilus influenzae</em></td>
</tr>
<tr>
<td><em>Haemophilus parainfluenzae</em></td>
</tr>
<tr>
<td><em>Klebsiella oxytoca</em></td>
</tr>
<tr>
<td><em>Klebsiella pneumoniae</em></td>
</tr>
<tr>
<td><em>Moraxella catarrhalis</em></td>
</tr>
<tr>
<td><em>Morganella morganii</em></td>
</tr>
<tr>
<td><em>Proteus mirabilis</em></td>
</tr>
<tr>
<td><em>Proteus vulgaris</em></td>
</tr>
<tr>
<td><em>Serratia marcescens</em></td>
</tr>
<tr>
<td><strong>Anaerobes:</strong></td>
</tr>
<tr>
<td><em>Clostridium</em> species (excluding <em>C. difficile)</em></td>
</tr>
<tr>
<td><em>Eubacterium</em> species*</td>
</tr>
<tr>
<td><em>Fusobacterium</em> species*</td>
</tr>
<tr>
<td><em>Peptostreptococcus</em> species*</td>
</tr>
<tr>
<td><em>Porphyromonas asaccharolytica</em></td>
</tr>
<tr>
<td><em>Prevotella</em> species*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species for which acquired resistance may be a problem:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gram-positive aerobes:</strong></td>
</tr>
</tbody>
</table>
| Methicillin-resistant staphylococci *+*#
| **Anaerobes:** |
| *Bacteroides fragilis* and species in the *B. fragilis* Group* |

<table>
<thead>
<tr>
<th>Inherently resistant organisms:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gram-positive aerobes:</strong></td>
</tr>
<tr>
<td><em>Corynebacterium jeikeium</em></td>
</tr>
<tr>
<td><strong>Enterococci including <em>Enterococcus faecalis</em> and <em>Enterococcus faecium</em></strong></td>
</tr>
</tbody>
</table>
Gram-negative aerobes:
Aeromonas species
Acinetobacter species
Burkholderia cepacia
Pseudomonas aeruginosa
Stenotrophomonas maltophilia

Anaerobes:
Lactobacillus species

Others:
Chlamydia species
Mycoplasma species
Rickettsia species
Legionella species

* Activity has been satisfactorily demonstrated in clinical studies.
† The efficacy of INVANZ in the treatment of community acquired pneumonia due to penicillin-resistant
  Streptococcus pneumoniae has not been established.
+ frequency of acquired resistance > 50% in some Member States.
# Methicillin-resistant staphylococci (including MRSA) are always resistant to beta-lactams.

**Information from clinical studies**

**Efficacy in Paediatric Studies**
Ertapenem was evaluated primarily for paediatric safety and secondarily for efficacy in randomised
comparative, multicentre studies in patients 3 months to 17 years of age.

The proportion of patients with a favourable clinical response assessment at posttreatment visit in the
clinical MITT population is shown below:

<table>
<thead>
<tr>
<th>Disease Stratum†</th>
<th>Age Stratum</th>
<th>Ertapenem</th>
<th>Ceftriaxone</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>n/m</td>
<td>%</td>
</tr>
<tr>
<td>Community Acquired Pneumonia (CAP)</td>
<td>3 to 23 months</td>
<td>31/35</td>
<td>88.6</td>
</tr>
<tr>
<td></td>
<td>2 to 12 years</td>
<td>55/57</td>
<td>96.5</td>
</tr>
<tr>
<td></td>
<td>13 to 17 years</td>
<td>3/3</td>
<td>100.0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Disease Stratum</th>
<th>Age Stratum</th>
<th>Ertapenem</th>
<th>Ticarcillin/clavulanate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intraabdominal Infections (IAI)</td>
<td>2 to 12 years</td>
<td>28/34</td>
<td>7/9</td>
</tr>
<tr>
<td></td>
<td>13 to 17 years</td>
<td>15/16</td>
<td>4/6</td>
</tr>
<tr>
<td>Acute Pelvic Infections (API)</td>
<td>13 to 17 years</td>
<td>25/25</td>
<td>8/8</td>
</tr>
</tbody>
</table>

† This includes 9 patients in the ertapenem group (7 CAP and 2 IAI), 2 patients in the ceftriaxone group (2 CAP), and 1 patient with IAI in the ticarcillin/clavulanate group with secondary bacteraemia at entry into the study.

**5.2 Pharmacokinetic properties**

**Plasma concentrations**
Average plasma concentrations of ertapenem following a single 30 minute intravenous infusion of a
1 g dose in healthy young adults (25 to 45 years of age) were 155 micrograms/mL ($C_{\text{max}}$) at 0.5 hour
postdose (end of infusion), 9 micrograms/mL at 12 hour postdose, and 1 microgram/mL at 24 hour
postdose.

Area under the plasma concentration curve (AUC) of ertapenem in adults increases nearly dose-
proportionally over the 0.5 to 2 g dose range.

There is no accumulation of ertapenem in adults following multiple intravenous doses ranging from
0.5 to 2 g daily.
Average plasma concentrations of ertapenem following a single 30 minute intravenous infusion of a 15 mg/kg (up to a maximum dose of 1 g) dose in patients 3 to 23 months of age were 103.8 micrograms/mL (C_{max}) at 0.5 hour postdose (end of infusion), 13.5 micrograms/mL at 6 hour postdose, and 2.5 micrograms/mL at 12 hour postdose.

Average plasma concentrations of ertapenem following a single 30 minute intravenous infusion of a 15 mg/kg (up to a maximum dose of 1 g) dose in patients 2 to 12 years of age were 113.2 micrograms/mL (C_{max}) at 0.5 hour postdose (end of infusion), 12.8 micrograms/mL at 6 hour postdose, and 3.0 micrograms/mL at 12 hour postdose.

Average plasma concentrations of ertapenem following a single 30 minute intravenous infusion of a 20 mg/kg (up to a maximum dose of 1 g) dose in patients 13 to 17 years of age were 170.4 micrograms/mL (C_{max}) at 0.5 hour postdose (end of infusion), 7.0 micrograms/mL at 12 hour postdose, and 1.1 microgram/mL at 24 hour postdose.

Average plasma concentrations of ertapenem following a single 30 minute intravenous infusion of a 1 g dose in three patients 13 to 17 years of age were 155.9 micrograms/mL (C_{max}) at 0.5 hour postdose (end of infusion), and 6.2 micrograms/mL at 12 hour postdose.

Distribution
Ertapenem is highly bound to human plasma proteins. In healthy young adults (25 to 45 years of age), the protein binding of ertapenem decreases, as plasma concentrations increase, from approximately 95 % bound at an approximate plasma concentration of < 50 micrograms/mL to approximately 92 % bound at an approximate plasma concentration of 155 micrograms/mL (average concentration achieved at the end of infusion following 1 g intravenously).

The volume of distribution (V_{dss}) of ertapenem in adults is approximately 8 litres (0.11 litre/kg) and approximately 0.2 litre/kg in paediatric patients 3 months to 12 years of age and approximately 0.16 litre/kg in paediatric patients 13 to 17 years of age.

Concentrations of ertapenem achieved in adult skin blister fluid at each sampling point on the third day of 1 g once daily intravenous doses showed a ratio of AUC in skin blister fluid: AUC in plasma of 0.61.

In vitro studies indicate that the effect of ertapenem on the plasma protein binding of highly protein bound medicinal products (warfarin, ethinyl estradiol, and norethindrone) was small. The change in binding was < 12 % at peak plasma ertapenem concentration following a 1 g dose. In vivo, probenecid (500 mg every 6 hours) decreased the bound fraction of ertapenem in plasma at the end of infusion in subjects administered a single 1 g intravenous dose from approximately 91 % to approximately 87 %. The effects of this change are anticipated to be transient. A clinically significant interaction due to ertapenem displacing another medicinal product or another medicinal product displacing ertapenem is unlikely.

In vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of digoxin or vinblastine and that ertapenem is not a substrate for P-glycoprotein-mediated transport.

Biotransformation
In healthy young adults (23 to 49 years of age), after intravenous infusion of radiolabelled 1 g ertapenem, the plasma radioactivity consists predominantly (94 %) of ertapenem. The major metabolite of ertapenem is the ring-opened derivative formed by dehydropeptidase-I-mediated hydrolysis of the beta-lactam ring.

In vitro studies in human liver microsomes indicate that ertapenem does not inhibit metabolism mediated by any of the six major CYP isoforms: 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4.
Elimination
Following administration of a 1 g radiolabelled intravenous dose of ertapenem to healthy young adults (23 to 49 years of age), approximately 80% is recovered in urine and 10% in faeces. Of the 80% recovered in urine, approximately 38% is excreted as unchanged ertapenem and approximately 37% as the ring-opened metabolite.

In healthy young adults (18 to 49 years of age) and patients 13 to 17 years of age given a 1 g intravenous dose, the mean plasma half-life is approximately 4 hours. The mean plasma half-life in children 3 months to 12 years of age is approximately 2.5 hours. Average concentrations of ertapenem in urine exceed 984 micrograms/mL during the period 0 to 2 hours postdose and exceed 52 micrograms/mL during the period 12 to 24 hours post-administration.

Special populations

Gender
The plasma concentrations of ertapenem are comparable in men and women.

Elderly
Plasma concentrations following a 1 g and 2 g intravenous dose of ertapenem are slightly higher (approximately 39% and 22%, respectively) in healthy elderly adults (≥65 years) relative to young adults (<65 years). In the absence of severe renal impairment, no dosage adjustment is necessary in elderly patients.

Paediatric population
Plasma concentrations of ertapenem are comparable in paediatric patients 13 to 17 years of age and adults following a 1 g once daily intravenous dose.

Following the 20 mg/kg dose (up to a maximum dose of 1 g), the pharmacokinetic parameter values in patients 13 to 17 years of age were generally comparable to those in healthy young adults. To provide an estimate of the pharmacokinetic data if all patients in this age group were to receive a 1 g dose, the pharmacokinetic data were calculated adjusting for a 1 g dose, assuming linearity. A comparison of results show that a 1 g once daily dose of ertapenem achieves a pharmacokinetic profile in patients 13 to 17 years of age comparable to that of adults. The ratios (13 to 17 years/adults) for AUC, the end of infusion concentration and the concentration at the midpoint of the dosing interval were 0.99, 1.20, and 0.84, respectively.

Plasma concentrations at the midpoint of the dosing interval following a single 15 mg/kg intravenous dose of ertapenem in patients 3 months to 12 years of age are comparable to plasma concentrations at the midpoint of the dosing interval following a 1 g once daily intravenous dose in adults (see Plasma concentrations). The plasma clearance (mL/min/kg) of ertapenem in patients 3 months to 12 years of age is approximately 2-fold higher as compared to that in adults. At the 15 mg/kg dose, the AUC value and plasma concentrations at the midpoint of the dosing interval in patients 3 months to 12 years of age were comparable to those in young healthy adults receiving a 1 g intravenous dose of ertapenem.

Hepatic impairment
The pharmacokinetics of ertapenem in patients with hepatic impairment have not been established. Due to the limited extent of hepatic metabolism of ertapenem, its pharmacokinetics are not expected to be affected by hepatic impairment. Therefore, no dosage adjustment is recommended in patients with hepatic impairment.

Renal impairment
Following a single 1 g intravenous dose of ertapenem in adults, AUCs of total ertapenem (bound and unbound) and of unbound ertapenem are similar in patients with mild renal impairment (Clcr 60 to 90 mL/min/1.73 m²) compared with healthy subjects (ages 25 to 82 years). AUCs of total ertapenem and of unbound ertapenem are increased in patients with moderate renal impairment (Clcr 31 to 59 mL/min/1.73 m²) approximately 1.5-fold and 1.8-fold, respectively, compared with healthy subjects. AUCs of total ertapenem and of unbound ertapenem are increased in patients with severe
renal impairment (ClCr 5 to 30 mL/min/1.73 m²) approximately 2.6-fold and 3.4-fold, respectively, compared with healthy subjects. AUCs of total ertapenem and of unbound ertapenem are increased in patients who require haemodialysis approximately 2.9-fold and 6.0-fold, respectively, between dialysis sessions, compared with healthy subjects. Following a single 1 g intravenous dose given immediately prior to a haemodialysis session, approximately 30% of the dose is recovered in the dialysate. There are no data in paediatric patients with renal impairment.

There are inadequate data on the safety and efficacy of ertapenem in patients with advanced renal impairment and patients who require haemodialysis to support a dose recommendation. Therefore, ertapenem should not be used in these patients.

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety, pharmacology, repeated dose toxicity, genotoxicity and toxicity to reproduction and development. Decreased neutrophil counts, however, occurred in rats that received high doses of ertapenem, which was not considered a significant safety issue.

Long-term studies in animals to evaluate the carcinogenic potential of ertapenem have not been performed.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sodium bicarbonate (E500)
Sodium hydroxide (E524) to adjust pH to 7.5

6.2 Incompatibilities

Do not use solvents or infusion fluids containing dextrose for reconstitution or administration of ertapenem.

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

6.3 Shelf life

2 years.

After reconstitution: Diluted solutions should be used immediately. If not used immediately, in use storage times are the responsibility of the user. Diluted solutions (approximately 20 mg/mL ertapenem) are physically and chemically stable for 6 hours at room temperature (25°C) or for 24 hours at 2 to 8°C (in a refrigerator). Solutions should be used within 4 hours of their removal from the refrigerator. Do not freeze solutions of INVANZ.

6.4 Special precautions for storage

Do not store above 25°C.

For storage conditions after reconstitution of the medicinal product, see section 6.3.

6.5 Nature and contents of container

15 mL Type I glass vials with a grey butyl stopper and a white plastic cap on a coloured aluminium band seal.
Supplied in packs of 1 vial or 10 vials.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

Instructions for use:

For single use only.

Reconstituted solutions should be diluted in sodium chloride 9 mg/mL (0.9 %) solution immediately after preparation.

*Preparation for intravenous administration:*

**INVANZ must be reconstituted and then diluted prior to administration.**

**Adults and adolescents (13 to 17 years of age)**

**Reconstitution**

Reconstitute the contents of a 1 g vial of INVANZ with 10 mL of water for injection or sodium chloride 9 mg/mL (0.9 %) solution to yield a reconstituted solution of approximately 100 mg/mL. Shake well to dissolve. (See section 6.4.)

**Dilution**

For a 50 mL bag of diluent: For a 1 g dose, immediately transfer contents of the reconstituted vial to a 50 mL bag of sodium chloride 9 mg/mL (0.9 %) solution; or

For a 50 mL vial of diluent: For a 1 g dose, withdraw 10 mL from a 50 mL vial of sodium chloride 9 mg/mL (0.9 %) solution and discard. Transfer the contents of the reconstituted 1 g vial of INVANZ to the 50 mL vial of sodium chloride 9 mg/mL (0.9 %) solution.

**Infusion**

Infuse over a period of 30 minutes.

**Children (3 months to 12 years of age)**

**Reconstitution**

Reconstitute the contents of a 1 g vial of INVANZ with 10 mL of water for injection or sodium chloride 9 mg/mL (0.9 %) solution to yield a reconstituted solution of approximately 100 mg/mL. Shake well to dissolve. (See section 6.4.)

**Dilution**

For a bag of diluent: Transfer a volume equal to 15 mg/kg of body weight (not to exceed 1 g/day) to a bag of sodium chloride 9 mg/mL (0.9 %) solution for a final concentration of 20 mg/mL or less; or

For a vial of diluent: Transfer a volume equal to 15 mg/kg of body weight (not to exceed 1 g/day) to a vial of sodium chloride 9 mg/mL (0.9 %) solution for a final concentration of 20 mg/mL or less.

**Infusion**

Infuse over a period of 30 minutes.

Compatibility of INVANZ with intravenous solutions containing heparin sodium and potassium chloride has been demonstrated.

The reconstituted solutions should be inspected visually for particulate matter and discolouration prior to administration, whenever the container permits. Solutions of INVANZ range from colourless to pale yellow. Variations of colour within this range do not affect potency.

Any unused product or waste material should be disposed of in accordance with local requirements.
7. MARKETING AUTHORISATION HOLDER

Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
The Netherlands

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/02/216/001
EU/1/02/216/002

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 18 April 2002
Date of latest renewal: 22 December 2011

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
ANNEX II

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer(s) responsible for batch release

FAREVA Mirabel, Route de Marsat, Riom
63963 Clermont-Ferrand Cedex 9, France

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to medical prescription.

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic safety update reports (PSURs)

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk management plan (RMP)

Not applicable.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON

1. NAME OF THE MEDICINAL PRODUCT

INVANZ 1 g powder for concentrate for solution for infusion ertapenem

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each vial contains: 1.0 g ertapenem (as sodium).

3. LIST OF EXCIPIENTS

Sodium bicarbonate (E500); sodium hydroxide (E524) to adjust pH to 7.5.

4. PHARMACEUTICAL FORM AND CONTENTS

Powder for concentrate for solution for infusion
1 vial
10 vials

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Intravenous use after reconstitution and dilution.
For single use only.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Do not store above 25°C
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/02/216/001 1 vial
EU/1/02/216/002 10 vials

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Justification for not including Braille accepted.

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN
## Minimum particulars to appear on small immediate packaging units

### Vial label

#### 1. Name of the medicinal product and route(s) of administration

INVANZ 1 g powder for concentrate for solution for infusion  
ertapenem  
Intravenous use

#### 2. Method of administration

Read the package leaflet before use.  
For single use only.

#### 3. Expiry date

EXP

#### 4. Batch number

Batch

#### 5. Contents by weight, by volume or by unit

1 g

#### 6. Other
B. PACKAGE LEAFLET
INVANZ contains ertapenem which is an antibiotic of the beta-lactam group. It has the ability to kill a wide range of bacteria (germs) that cause infections in various parts of the body.

INVANZ can be given to persons 3 months of age and older.

Treatment:
Your doctor has prescribed INVANZ because you or your child has one (or more) of the following types of infection:
- Infection in the abdomen
- Infection affecting the lungs (pneumonia)
- Gynaecological infections
- Skin infections of the foot in diabetic patients.

Prevention:
- Prevention of surgical site infections in adults following surgery of the colon or rectum.

2. What you need to know before you are given INVANZ

Do not use INVANZ
- if you are allergic to the active substance (ertapenem) or any of the other ingredients of this medicine (listed in section 6)
- if you are allergic to antibiotics such as penicillins, cephalosporins or carbapenems (which are used to treat various infections).

Warnings and precautions
Talk to your doctor, nurse or pharmacist before taking INVANZ.

During treatment, if you experience an allergic reaction (such as swelling of the face, tongue or throat, difficulty in breathing or swallowing, skin rash), tell your doctor straight away as you may need urgent medical treatment.
While antibiotics including INVANZ kill certain bacteria, other bacteria and fungi may continue to grow more than normal. This is called overgrowth. Your doctor will monitor you for overgrowth and treat you if necessary.

It is important that you tell your doctor if you have diarrhoea before, during or after your treatment with INVANZ. This is because you may have a condition known as colitis (an inflammation of the bowel). Do not take any medicine to treat diarrhoea without first checking with your doctor.

Tell your doctor if you are taking medicines called valproic acid or sodium valproate (see Other medicines and INVANZ below).

Tell your doctor about any medical condition you have or have had including:
- Kidney disease. It is particularly important that your doctor knows if you have kidney disease and whether you undergo dialysis treatment.
- Allergies to any medicines, including antibiotics.
- Central nervous system disorders, such as localised tremors, or seizures.

Children and adolescents (3 months to 17 years of age)
Experience with INVANZ is limited in children less than two years of age. In this age group your doctor will decide on the potential benefit of its use. There is no experience in children under 3 months of age.

Other medicines and INVANZ
Tell your doctor if you are taking, have recently taken or might take any other medicines.

Tell your doctor, nurse or pharmacist if you are taking medicines called valproic acid or sodium valproate (used to treat epilepsy, bipolar disorder, migraines, or schizophrenia). This is because INVANZ can affect the way some other medicines work. Your doctor will decide whether you should use INVANZ in combination with these other medicines.

Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.

INVANZ has not been studied in pregnant women. INVANZ should not be used during pregnancy unless your doctor decides the potential benefit justifies the potential risk to the foetus.

Women who are receiving INVANZ should not breast-feed, because it has been found in human milk and the breast-fed baby may therefore be affected.

Driving and using machines
Do not drive or use any tools or machines until you know how you react to the medicine. Certain side effects, such as dizziness and sleepiness, have been reported with INVANZ, which may affect some patients’ ability to drive or operate machinery.

INVANZ contains sodium
This medicine contains approximately 137 mg sodium (main component of cooking / table salt) in each 1.0 g dose. This is equivalent to 6.85 % of the recommended maximum daily dietary intake of sodium for an adult.

3. How to use INVANZ
INVANZ will always be prepared and given to you intravenously (into a vein) by a doctor or another healthcare professional.
The recommended dose of INVANZ for adults and adolescents 13 years of age and older is 1 gram (g) given once a day. The recommended dose for children 3 months to 12 years of age is 15 mg/kg given twice daily (not to exceed 1 g/day). Your doctor will decide how many days’ treatment you need.

For prevention of surgical site infections following surgery of the colon or rectum, the recommended dose of INVANZ is 1 g administered as a single intravenous dose 1 hour before surgery.

It is very important that you continue to receive INVANZ for as long as your doctor prescribes it.

If you are given more INVANZ than you should
If you are concerned that you may have been given too much INVANZ, contact your doctor or another healthcare professional immediately.

If you miss a dose of INVANZ
If you are concerned that you may have missed a dose, contact your doctor or another healthcare professional immediately.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Adults 18 years of age and older:

Since the drug has been marketed, severe allergic reactions (anaphylaxis), hypersensitivity syndromes (allergic reactions including rash, fever, abnormal blood tests) have been reported. The first signs of a severe allergic reaction may include swelling of the face and/or throat. If these symptoms occur tell your doctor straight away as you may need urgent medical treatment.

Common (may affect up to 1 in 10 people) side effects are:
- Headache
- Diarrhoea, nausea, vomiting
- Rash, itching
- Problems with the vein into which the medicine is given (including inflammation, formation of a lump, swelling at the injection site, or leaking of fluid into the tissue and skin around the injection site)
- Increase in platelet count
- Changes in liver function tests

Uncommon (may affect up to 1 in 100 people) side effects are:
- Dizziness, sleepiness, sleeplessness, confusion, seizure
- Low blood pressure, slow heart rate
- Shortness of breath, sore throat
- Constipation, yeast infection of the mouth, antibiotic-associated diarrhoea, acid regurgitation, dry mouth, indigestion, loss of appetite
- Skin redness
- Vaginal discharge and irritation
- Abdominal pain, fatigue, fungal infection, fever, oedema/swelling, chest pain, abnormal taste
- Changes in some laboratory blood and urine tests

Rare (may affect up to 1 in 1,000 people) side effects are:
- Decrease in white blood cells, decrease in blood platelet count
- Low blood sugar
- Agitation, anxiety, depression, tremor
- Irregular heart rate, increased blood pressure, bleeding, fast heart rate
• Nasal congestion, cough, bleeding from the nose, pneumonia, abnormal breathing sounds, wheezing
• Inflammation of the gall bladder, difficulty in swallowing, faecal incontinence, jaundice, liver disorder
• Inflammation of the skin, fungal infection of the skin, skin peeling, infection of the wound after an operation
• Muscle cramp, shoulder pain
• Urinary tract infection, kidney impairment
• Miscarriage, genital bleeding
• Allergy, feeling unwell, pelvic peritonitis, changes to the white part of the eye, fainting.
• The skin may become hard at the site of injection
• Swelling of the skin blood vessels

Side effects reported with frequency not known (frequency cannot be estimated from the available data) are:
• hallucinations
• decreased consciousness
• altered mental status (including aggression, delirium, disorientation, mental status changes)
• abnormal movements
• muscle weakness
• unsteady walking
• teeth staining

There have also been reports of changes in some laboratory blood tests.

If you experience raised or fluid-filled skin spots over a large area of your body, tell your doctor or nurse straight away.

**Children and adolescents (3 months to 17 years of age):**

Common (may affect up to 1 in 10 people) side effects are:
• Diarrhoea
• Diaper rash
• Pain at the infusion site
• Changes in white blood cell count
• Changes in liver function tests

Uncommon (may affect up to 1 in 100 people) side effects are:
• Headache
• Hot flush, high blood pressure, red or purple, flat, pinhead spots under the skin
• Discoloured faeces, black tar-like faeces
• Skin redness, skin rash
• Burning, itching, redness and warmth at infusion site, redness at injection site
• Increase in platelet count
• Changes in some laboratory blood tests

Side effects reported with frequency not known (frequency cannot be estimated from the available data) are:
• Hallucinations
• Altered mental status (including aggression)

**Reporting of side effects**
If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting
By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store INVANZ

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the container. The first 2 numbers indicate the month; the next 4 numbers indicate the year.

Do not store above 25°C

6. Contents of the pack and other information

What INVANZ contains
The active ingredient of INVANZ is ertapenem 1 g.
The other ingredients are: sodium bicarbonate (E500) and sodium hydroxide (E524).

What INVANZ looks like and contents of the pack
INVANZ is a white to off-white, freeze-dried powder for concentrate for solution for infusion.
Solutions of INVANZ range from colourless to pale yellow. Variations of colour within this range do not affect potency.

INVANZ is supplied in packs of 1 vial or 10 vials.
Not all pack sizes may be marketed.

Marketing Authorisation Holder
Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
The Netherlands

Manufacturer
FAREVA Mirabel
Route de Marsat, Riom
63963 Clermont-Ferrand Cedex 9
France

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

Belgique/Belgie/Belgien
MSD Belgium
Tél/Tel:+32(0)27766211
dpoc_belux@msd.com

Lietuva
UAB Merck Sharp & Dohme
Tel. + 370 5 278 02 47
msd_lietuva@merck.com

България
Мерк Шарп и Доум България ЕООД
Тел.: +359 2 819 3737
info-msdbg@merck.com

Luxembourg/Luxemburg
MSD Belgium
Tél/Tel: +32(0)27766211
dpoc_belux@msd.com
<table>
<thead>
<tr>
<th>Country</th>
<th>Address</th>
<th>Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Česká republika</td>
<td>Merck Sharp &amp; Dohme s.r.o.</td>
<td>Tel.: +420 233 010 111 <a href="mailto:dpoc_czechslovak@merck.com">dpoc_czechslovak@merck.com</a></td>
</tr>
<tr>
<td>Danmark</td>
<td>MSD Danmark ApS</td>
<td>Tel.: +45 44 82 40 00 <a href="mailto:dkmail@merck.com">dkmail@merck.com</a></td>
</tr>
<tr>
<td>Deutschland</td>
<td>INFECTOPHARM Arzneimittel und Consilium GmbH</td>
<td>Tel. +49 (0)6252 / 95-7000 <a href="mailto:kontakt@infectopharm.com">kontakt@infectopharm.com</a></td>
</tr>
<tr>
<td>Eesti</td>
<td>Merck Sharp &amp; Dohme OÜ</td>
<td>Tel.: +372 6144 200 <a href="mailto:msdeesti@merck.com">msdeesti@merck.com</a></td>
</tr>
<tr>
<td>Elláda</td>
<td>MSD Α.Φ.Ε.E.</td>
<td>Tel.: +30 210 98 97 300 <a href="mailto:dpoc_greece@merck.com">dpoc_greece@merck.com</a></td>
</tr>
<tr>
<td>España</td>
<td>Merck Sharp &amp; Dohme de España, S.A.</td>
<td>Tel: +34 91 321 06 00 <a href="mailto:msd_info@merck.com">msd_info@merck.com</a></td>
</tr>
<tr>
<td>Francia</td>
<td>MSD France</td>
<td>Tel: +33 (0) 1 80 46 40 40</td>
</tr>
<tr>
<td>Hrvatska</td>
<td>Merck Sharp &amp; Dohme d.o.o.</td>
<td>Tel: +385 1 6611 333 <a href="mailto:croatia_info@merck.com">croatia_info@merck.com</a></td>
</tr>
<tr>
<td>Ireland</td>
<td>Merck Sharp &amp; Dohme Ireland (Human Health) Limited</td>
<td>Tel: +353 (0)1 2998700 <a href="mailto:medinfo_ireland@msd.com">medinfo_ireland@msd.com</a></td>
</tr>
<tr>
<td>Island</td>
<td>Vistor hf.</td>
<td>Sími: +354 535 7000</td>
</tr>
<tr>
<td>Italia</td>
<td>MSD Italia S.r.l.</td>
<td>Tel: 800 23 99 89 (+39 06 361911) <a href="mailto:medicalinformation.it@msd.com">medicalinformation.it@msd.com</a></td>
</tr>
<tr>
<td>Magyarország</td>
<td>MSD Pharma Hungary Kft.</td>
<td>Tel.: +361 888 53 00 <a href="mailto:hungary_msd@merck.com">hungary_msd@merck.com</a></td>
</tr>
<tr>
<td>Malta</td>
<td>Merck Sharp &amp; Dohme Cyprus Limited</td>
<td>Tel: 8007 4433 (+356 99917558) <a href="mailto:malta_info@merck.com">malta_info@merck.com</a></td>
</tr>
<tr>
<td>Nederland</td>
<td>Merck Sharp &amp; Dohme B.V.</td>
<td>Tel: 0800 9999000 (+31 (0)23 5153153) <a href="mailto:medicalinfo.nl@merck.com">medicalinfo.nl@merck.com</a></td>
</tr>
<tr>
<td>Norge</td>
<td>MSD (Norge) AS</td>
<td>Tel: +47 32 20 73 00 <a href="mailto:msdnorge@msd.no">msdnorge@msd.no</a></td>
</tr>
<tr>
<td>Österreich</td>
<td>Merck Sharp &amp; Dohme Ges.m.b.H.</td>
<td>Tel: +43 (0) 1 26 044 <a href="mailto:dpoc_austria@merck.com">dpoc_austria@merck.com</a></td>
</tr>
<tr>
<td>Polska</td>
<td>MSD Polska Sp.z o.o.</td>
<td>Tel.: +48 22 549 51 00 <a href="mailto:msdpolska@merck.com">msdpolska@merck.com</a></td>
</tr>
<tr>
<td>Portugal</td>
<td>Merck Sharp &amp; Dohme, Lda</td>
<td>Tel: +351 21 4465700 <a href="mailto:inform_pt@merck.com">inform_pt@merck.com</a></td>
</tr>
<tr>
<td>România</td>
<td>Merck Sharp &amp; Dohme Romania S.R.L.</td>
<td>Tel: +4021 529 29 00 <a href="mailto:msdromania@merck.com">msdromania@merck.com</a></td>
</tr>
<tr>
<td>Slovenija</td>
<td>Merck Sharp &amp; Dohme, inovativna zdravila d.o.o.</td>
<td>Tel: +386 1 5204201 <a href="mailto:msd_slovenia@merck.com">msd_slovenia@merck.com</a></td>
</tr>
<tr>
<td>Slovenská republika</td>
<td>Merck Sharp &amp; Dohme, s. r. o.</td>
<td>Tel.: +421 2 58282010 <a href="mailto:dpoc_czechslovak@merck.com">dpoc_czechslovak@merck.com</a></td>
</tr>
<tr>
<td>Suomi/Finland</td>
<td>MSD Finland Oy</td>
<td>Puh/Tel: +358 (0) 9 804650 <a href="mailto:info@msd.fi">info@msd.fi</a></td>
</tr>
</tbody>
</table>
Instructions of how to reconstitute and dilute INVANZ:

For single use only.

Preparation for intravenous administration:
INVANZ must be reconstituted and then diluted prior to administration.

Adult and adolescents (13 to 17 years of age)
Reconstitution
Reconstitute the contents of a 1 g vial of INVANZ with 10 mL of water for injection or sodium chloride 9 mg/mL (0.9 %) solution to yield a reconstituted solution of approximately 100 mg/mL. Shake well to dissolve.

Dilution
For a 50 mL bag of diluent: For a 1 g dose, immediately transfer contents of the reconstituted vial to a 50 mL bag of sodium chloride 9 mg/mL (0.9 %) solution; or

For a 50 mL vial of diluent: For a 1 g dose, withdraw 10 mL from a 50 mL vial of sodium chloride 9 mg/mL (0.9 %) solution and discard. Transfer the contents of the reconstituted 1 g vial of INVANZ to the 50 mL vial of sodium chloride 9 mg/mL (0.9 %) solution.

Infusion
Infuse over a period of 30 minutes.

Children (3 months to 12 years of age)
Reconstitution
Reconstitute the contents of a 1 g vial of INVANZ with 10 mL of water for injection or sodium chloride 9 mg/mL (0.9 %) solution to yield a reconstituted solution of approximately 100 mg/mL. Shake well to dissolve.

Dilution
For a bag of diluent: Transfer a volume equal to 15 mg/kg of body weight (not to exceed 1 g/day) to a bag of sodium chloride 9 mg/mL (0.9 %) solution for a final concentration of 20 mg/mL or less; or

For a vial of diluent: Transfer a volume equal to 15 mg/kg of body weight (not to exceed 1 g/day) to a vial of sodium chloride 9 mg/mL (0.9 %) solution for a final concentration of 20 mg/mL or less.

Infusion
Infuse over a period of 30 minutes.

The reconstituted solution should be diluted in sodium chloride 9 mg/mL (0.9 %) solution immediately after preparation. Diluted solutions should be used immediately. If not used immediately, in use storage times are the responsibility of the user. Diluted solutions (approximately 20 mg/mL
ertapenem) are physically and chemically stable for 6 hours at room temperature (25°C) or for 24 hours at 2 to 8°C (in a refrigerator). Solutions should be used within 4 hours of their removal from the refrigerator. Do not freeze the reconstituted solutions.

The reconstituted solutions should be inspected visually for particulate matter and discolouration prior to administration, whenever the container permits. Solutions of INVANZ range from colourless to pale yellow. Variations of colour within this range do not affect potency.

Any unused product or waste material should be disposed of in accordance with local requirements.